Cargando…

Two Cases of Nivolumab Re-Administration after Pneumonitis as Immune-Related Adverse Events

Nivolumab is a recently approved medication for the treatment of unresectable malignant melanoma. Many immune-related adverse events (irAEs) associated with nivolumab have been reported, such as pneumonitis, hepatitis, dermatitis, and thyroiditis. Prednisolone can effectively treat irAEs. However, i...

Descripción completa

Detalles Bibliográficos
Autores principales:	Imafuku, Keisuke, Yoshino, Koji, Yamaguchi, Kei, Tsuboi, Satoshi, Ohara, Kuniaki, Hata, Hiroo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	S. Karger AG 2017
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5422733/ https://www.ncbi.nlm.nih.gov/pubmed/28512413 http://dx.doi.org/10.1159/000463379

Ejemplares similares

Successful Treatment of Sudden Hepatitis Induced by Long-Term Nivolumab Administration
por: Imafuku, Keisuke, et al.
Publicado: (2017)

Sudden Onset of Brain Metastasis despite the Use of Vemurafenib for Another Metastatic Lesion in Malignant Melanoma Patients
por: Imafuku, Keisuke, et al.
Publicado: (2017)

Comment on ‘Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy'
por: Imafuku, Keisuke, et al.
Publicado: (2017)

Serum levels of soluble CD163 and CXCL5 may be predictive markers for immune-related adverse events in patients with advanced melanoma treated with nivolumab: a pilot study
por: Fujimura, Taku, et al.
Publicado: (2018)

Enhanced IL-34 expression in Nivolumab-resistant metastatic melanoma
por: Han, Nanumi, et al.
Publicado: (2018)

Immune-Related Adverse Events: Pneumonitis
por: Zhong, Linda, et al.
Publicado: (2020)

Nivolumab: Interstitial pneumonitis: case report
Publicado: (2020)

Serious adverse events and fatal adverse events associated with nivolumab treatment in cancer patients: Nivolumab-related serious/fatal adverse events
por: Zhao, Bin, et al.
Publicado: (2018)

Adverse events induced by nivolumab and ipilimumab combination regimens
por: Somekawa, Kohei, et al.
Publicado: (2022)

Extracorporeal Membrane Oxygenation in Nivolumab Associated Pneumonitis
por: Schneider, Thomas-Michael, et al.
Publicado: (2017)

Ipilimumab/nivolumab: Diffuse pneumonitis: case report
Publicado: (2020)

Ipilimumab/nivolumab: Immune-related pneumonitis: 2 case reports
Publicado: (2020)

Serum Level of Soluble CD163 May Be a Predictive Marker of the Effectiveness of Nivolumab in Patients With Advanced Cutaneous Melanoma
por: Fujimura, Taku, et al.
Publicado: (2018)

Basal Cell Carcinoma or Trichoblastoma? Dermoscopic Examination of Black Macules Developing in the Same Nevus Sebaceus
por: Kitamura, Shinya, et al.
Publicado: (2016)

Risk of immune-related adverse events associated with ipilimumab-plus-nivolumab and nivolumab therapy in cancer patients
por: Zhou, Shi, et al.
Publicado: (2019)

Nivolumab-Induced Pneumonitis in a Patient With Urothelial Cancer
por: Kasi, Arbab Furquan Ud din, et al.
Publicado: (2023)

Severe colitis after PD-1 blockade with nivolumab in advanced melanoma patients: potential role of Th1-dominant immune response in immune-related adverse events: two case reports
por: Yoshino, Koji, et al.
Publicado: (2019)

Pre-existing interstitial lung disease is associated with onset of nivolumab-induced pneumonitis in patients with solid tumors: a retrospective analysis
por: Yamaguchi, Teppei, et al.
Publicado: (2021)

An Extremely Rapid Case of Pneumonitis with the Use of Nivolumab for Pancreatic Adenocarcinoma
por: Costa, Rubens Barros, et al.
Publicado: (2018)

Nivolumab for NSCLC in Japanese patients: similar benefits, but beware of pneumonitis
por: Vansteenkiste, Johan
Publicado: (2017)

Correction to: Serious adverse events and fatal adverse events associated with nivolumab treatment in cancer patients
por: Zhao, Bin, et al.
Publicado: (2019)

Sjögren's Syndrome as an Immune-related Adverse Event of Nivolumab Treatment for Gastric Cancer
por: Higashi, Tetsuo, et al.
Publicado: (2020)

Association of immune-related adverse events induced by nivolumab with a battery of autoantibodies
por: Les, Iñigo, et al.
Publicado: (2021)

A Case of Immune-Mediated Pneumonitis Associated With Dual Nivolumab and Ipilimumab Immunotherapy Treatment
por: Al-Saghir, Tala, et al.
Publicado: (2023)

Hypercalcemia with methotrexate pneumonitis: A rare, important and intriguing adverse event
por: Samant, R, et al.
Publicado: (2022)

Rare Adverse Events Related to Nivolumab, an Immune Checkpoint Inhibitor: A Case Series
por: Ganta, Nagapratap, et al.
Publicado: (2022)

Immune-related adverse events and prognosis in patients with upper gastrointestinal cancer treated with nivolumab
por: Hara, Yoshihiro, et al.
Publicado: (2022)

Improvement in recurring nivolumab-induced pneumonitis with repetitive administration of infliximab in a patient with head and neck cancer: A case report
por: Ueno, Shohei, et al.
Publicado: (2021)

Immune-related pneumonitis with nivolumab and ipilimumab during the coronavirus disease 2019 (COVID-19) pandemic
por: Souza, Ive L., et al.
Publicado: (2020)

A case report on severe nivolumab-induced adverse events similar to primary sclerosing cholangitis refractory to immunosuppressive therapy
por: Hirasawa, Yuya, et al.
Publicado: (2021)

Radiation recall pneumonitis induced by nivolumab in a patient with renal cell carcinoma
por: Nakamura, Kenji, et al.
Publicado: (2018)

Incidence, features, and prognosis of immune-related adverse events involving the thyroid gland induced by nivolumab
por: Yamauchi, Ichiro, et al.
Publicado: (2019)

Correlation between immune-related adverse events and prognosis in patients with gastric cancer treated with nivolumab
por: Masuda, Ken, et al.
Publicado: (2019)

Estimated Costs of the Ipilimumab–Nivolumab Therapy and Related Adverse Events in Metastatic Melanoma
por: Gautron Moura, Bianca, et al.
Publicado: (2022)

Evaluation of lung adverse events with nivolumab using the spontaneous reporting system in Japan
por: Kanbayashi, Yuko, et al.
Publicado: (2023)

Two cases of delayed onset of immune‐related adverse events after discontinuation of nivolumab in patients with metastatic renal cell cancer
por: Nakai, Yasutomo, et al.
Publicado: (2021)

Association of Baseline Serum Levels of CXCL5 With the Efficacy of Nivolumab in Advanced Melanoma
por: Fujimura, Taku, et al.
Publicado: (2019)

Concomitant Human Herpes Virus 6 and nivolumab-related pneumonitis: Potential pathogenetic insights
por: Foukas, Periklis G., et al.
Publicado: (2018)

SUN-414 Immune Related Adverse Events: Isolated ACTH Deficiency with Nivolumab/Ipilimumab Combination Therapy
por: Magdaleno, Angela, et al.
Publicado: (2019)

Frequency of pre-treatment may not increase the immune-related adverse events of RCC patients treated with nivolumab
por: Mizutani, Kosuke, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_k62snousbjsgbjtnmfc3u13h3u